Searle is a research-based company headquartered in Skokie, Illinois (USA) that develops, manufactures and markets prescription pharmaceuticals and other healthcare solutions worldwide. Its mission is to bring to the market innovative, value-added healthcare products that satisfy unmet medical needs.
Searle currently operates administrative offices in 34 countries, and manufacturing plants in 12. In addition, it maintains relationships with distributors, other pharmaceutical companies and similar local partners across the globe. Worldwide, Searle employs more than 8,500 individuals and in 1995, generated $1.7 billion in sales -- a 13 percent increase over the previous year.
The Searle family still owned all or a substantial portion of the publicly traded company until its acquisition by Monsanto Company in 1985. As a wholly owned subsidiary of Monsanto, Searle has the financial support to research and develop exciting new treatments, concentrating in the areas of arthritis and cardiovascular, immunoinflammatory and oncologic diseases. In addition, it now markets products and services designed to promote wellness, particularly in the areas of cardiovascular health, arthritis, reproductive health and sleep.
Searle's role in the origination and/or commercialization of many "firsts" is well documented. Examples include: the first modern bulk laxative, the first motion-sickness drug, the first oral contraceptive, the first modern antiarrhythmic, the first specific oral anti-diarrheal, the first once-a-day calcium channel blocker for the treatment of hypertension, and several other innovative products. Searle also discovered the first product proven to prevent gastric ulcers caused by nonsteroidal anti-inflammatory drugs (NSAIDs), compounds taken by millions of people worldwide who suffer from arthritis. Likewise, Searle discovered and introduced aspartame (NutraSweet® in the U.S. and Canderel® elsewhere), a hugely successful sugar substitute.
Searle also has a social-responsibility philosophy that makes it a leader in the pharmaceutical industry. For example, in a number of countries, Searle has launched Patient Partners in Arthritis. This unique network of specially trained persons with arthritis helps patients help each other -- and their physicians -- cope with the disease.
In addition, in the U.S., the Searle commitment to social responsibility is evident through three unique initiatives: the Patients in Need® Program, which provides life-saving Searle medication free of charge to people who otherwise could not afford it; the Patient Promise® Program, which provides refunds to patients if a Searle product does not achieve its desired therapeutic benefit; and the Patients in the Know® Program, which provides patients with easy-to-understand product information.